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The human G1m1 allotype associates with CD4þ T-cell
responsiveness to a highly conserved IgG1 constant
region peptide and confers an asparaginyl
endopeptidase cleavage site
MM Stickler, A Reddy, JM Xiong, PR Hinton, R DuBridge and FA Harding
Abbott Biotherapeutics, Redwood City, CA, USA
The human G1m1 allotype comprises two amino acids, D12 and L14, in the CH3 domain of IGHG1. Although the G1m1
allotype is prevalent in human populations, B40% of Caucasiods are homozygous for the nG1m1 allotype corresponding to
E12 and M14. Peptides derived from the G1m1 region were tested for their ability to induce CD4þ T-cell proliferative
responses in vitro. A peptide immediately downstream from the G1m1 sequence was recognized by CD4þ T cells in a large
percentage of donors (peptide CH315 29). CD4þ T-cell proliferative responses to CH315 29 were found at an increased
frequency in nG1m1 homozygous donors. Homozygous nG1m1 donors possessing the HLA-DRB1*07 allele displayed
the highest magnitudes of proliferation. CD4þ T cells from donors homozygous for nG1m1 proliferated to G1m1-carrying
Fc-fragment proteins, whereas CD4þ T cells from G1m1 homozygous donors did not. The G1m1 sequence creates an
enzymatic cleavage site for asparaginyl endopeptidase in vitro. Proteolytic activity at D12 may allow the presentation of the
CH315 29 peptide, which in turn may result in the establishment of tolerance to this peptide in G1m1-positive donors.
Homozygous nG1m1 patients may be more likely to develop CD4þ T-cell-mediated immune responses to therapeutic
antibodies carrying the G1m1 allotype.
Genes and Immunity (2011) 12, 213–221; doi:10.1038/gene.2010.68; published online 17 February 2011
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Introduction
The constant regions of immunoglobulin molecules
represent highly conserved multi-domain structures
that confer specific functional activities. There are
five distinct classes of immunoglobulin in humans: IgM,
IgD, IgG, IgE and IgA, with the IgG and IgA classes
comprising four and two subclasses, respectively (IgG1,
IgG2, IgG3, IgG4, IgA1 and IgA2).
1 Immunoglobulins are
expressed early during fetal development, and at high
concentrations in the serum.
2 Significant cellular toler-
ance to immunoglobulin constant regions is present, as
would be expected for any highly expressed, conserved
protein.
3–5
Allotypes of immunoglobulin exist within the g1, g2,
g3 and a isotypes of humans.
6–9 The G1m1 allotype (also
referred to as G1m(a)) in the g1 isotype is characterized
by two amino acids, aspartate and leucine, D12 and L14,
according to the IMGT unique numbering in the CH3
of IGHG1 (positions D356 and L358, respectively, in the
Eu gamma1 chain).
10 The absence of the G1m1 allotype
(hereto referred to as the nG1m1 allotype; also referred to
as nG1m(a)) is characterized by amino acids E12 and
M14 also observed in the CH3 domain of IGHG2, IGHG3
and IGHG4 and therefore, represents an isoallotype
for these subclasses (Figure 1a). The nG1m1 allotype is
typically found in conjunction with the G1m3 (or G1m(f))
allotype, and only in Caucasiods.
8The divergence of the
G1m1- and nG1m1-containing haplotype likely occurred
at the immigration of early humans to the European
continent 30000–35000 years ago, as assessed by the
accumulation of mutations within the haplotypes.
11
Immunoglobulin allotypes may be maintained in the
population through a currently uncharacterized hetero-
zygous advantage,
11 or through adaptations with respect
to viral diseases.
12,13
The G1m1 allotype in the CH3 domain can represent
an antibody epitope in vivo.
14,15 Anti-allotype anti-
bodies have been detected when individuals who do not
possess the allotype in their genome are exposed to
antibodies that carry the allotypic amino-acid sequence,
such as after platelet transfusion or after multiple child-
births
16–18 However, the presence of novel amino acids in a
normally conserved sequence may also function as a
CD4þ T helper cell epitope, as has been shown in mice.
19–23
Productive, cognate interactions between immunoglobu-
lin allotype-specific helper T cells and B cells in rodents
have been demonstrated in vitro.
24–27 Therefore, a CD4þ
T helper cell epitope in the constant region of an
exogenously administered antibody could potentially
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novel regions of the protein, as exemplified by the
complementarity determining regions, in humans. In such
an example, antibodies specific for the G1m1 sequence may
be undetectable but a specific CD4þ helper T-cell response
could be present. As a number of approved antibody
therapeutics contain the G1m1 allotype in their constant
regions, we examined the G1m1-containing region of
human IGHG1 CH3 for CD4þ T helper epitopes in vitro.
Results
Human CD4þ T-cell responses to the CH315 29 region of the
G1m1 and nG1m1 allotypes
A set of 14 peptides was constructed based on the
sequence of the IGHG1 CH3 domain encompassing
amino-acid positions 1.4–29, according to the IMGT
unique numbering system
10 (EU numbering 341–373
(Figure 1b, Table 1)). Peptides #1 and #7 were identical in
both sets. Peptides #2–6 differed at two amino acids, CH3
D124E and L144M (E356D and M358L). All peptides
were tested parametrically using a set of 80 community
donor samples (Figure 2). The results showed a
significant level of proliferative responses, both in the
percent of responding donors and in the overall average
magnitude of the response, at peptide #7. We confirmed
this result using a set of seven peptides corresponding to
peptides A1–A7 synthesized by a separate manufacturer
and tested with a subset of 50 community donor
samples. Again we saw a high percent response rate
(38%) and high average stimulation index (3.61) in
response to peptide #7. Finally, in a third confirmation
of this result, 15-mer peptides synthesized to represent
the entire CH2-CH3 Fc region of g1 were tested, and the
corresponding G1m1 allotype peptide region induced
responses in 20% of all donors with an average SI of 2.59
(data not shown). Peptide #7 is completely conserved
across all four IgG subclasses, and encompasses amino
acids 15–29 of the CH3 domain.
Response to CH315 29 is absent from donors homozygous for
the G1m1 allotype
All 80 community donor samples were assessed for
their genomic G1m1 status. Of the 80 donor samples,
28 were homozygous for nG1m1 (Figures 3a and b),
23 were homozygous for G1m1 (Figures 3c and d) and
29 were heterozygous (Figures 3e and f). It was clear that
the responses to CH315 29 were occurring in the hetero-
zygous and the nG1m1 homozygous donor samples.
I nt h en G 1 m 1d o n o r s ,1 2o f2 8w e r ep o s i t i v ef o r
proliferative responses to the peptide, whereas 3 and 4
donors in each test of the peptide were positive for
responses in the G1m1 homozygous donors. Heterozygous
donors responded at approximately the same rate as the
nG1m1 donors. This result suggests that CD4þ Tcellsfrom
donors with two copies of the G1m1 allotype selectively
lack the ability to proliferate in response to CH315 29.
HuG1  GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY…
HuG2  GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY…
HuG3  GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY…
HuG4  GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY…
HuG1  GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY…
HuG2  GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY…
HuG3  GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY…
HuG4  GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY…
G1m1 allotype
nG1m1 allotype
Figure 1 The G1m1 allotype of human IGHG1 CH3 occurs in a
highly conserved region. Amino-acid alignment of human IGHG1,
IGHG2, IGHG3 and IGHG4 CH3 domains between positions
corresponding to 1.4 to 30 of IGHG3 CH3. The G1m1 allotype
amino acids are underlined.
Table 1 Synthetic peptides corresponding to the G1m1 and
nG1m1 regions of the IGHG1 CH3 region.
Peptides Sequences Amino-acid numbers
1 GQPREPQVYTLPPSR CH3 1.4–11
A2 REPQVYTLPPSRDEL CH3 1–14
A3 QVYTLPPSRDELTKN CH3 3–17
A4 TLPPSRDELTKNQVS CH3 6–20
A5 PSRDELTKNQVSLTC CH3 9–23
A6 DELTKNQVSLTCLVK CH3 12–26
7 TKNQVSLTCLVKGFY CH3 15–29
1 GQPREPQVYTLPPSR CH3 1.4–11
N2 REPQVYTLPPSREEM CH3 1–14
N3 QVYTLPPSREEMTKN CH3 3–17
N4 TLPPSREEMTKNQVS CH3 6–20
N5 PSREEMTKNQVSLTC CH3 9–23
N6 EEMTKNQVSLTCLVK CH3 12–26
7 TKNQVSLTCLVKGFY CH3 15–29
Amino acid numbering follows the IMGT designation for CH3
(see ref. 10). Bold lettering indicates amino acids impacted by the
G1m1 allotype.
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Figure 2 CD4þ T-cell proliferative responses to the G1m1 and
nG1m1 peptides. A set of 80 donor samples was tested. A response
to a peptide was tabulated if the stimulation index was X2.95.
(a) Shows the percent responses to the peptides. (b) Shows the
average stimulation index±s.e.m. for all 80 donors. This result was
confirmed in an additional set of 50 donors, and with a second set of
peptides from a different manufacturer.
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Genes and ImmunityHeterozygous donors display an intermediate response to
CH315 29
Both the homozygous nG1m1 and the heterozygous
donors responded to CH315 29 with a stimulation index
of greater than 2.95 with an incidence of B40%.
However, the average magnitude of the response was
lower in heterozygous donors (Figure 4a). The difference
between the average response rate found with the
nG1m1 donors and the G1m1 homozygous donors was
highly significant (Student’s t-test, Po0.01). The differ-
ence between the responses of the heterozygous donors
and the G1m1 homozygous donors was lower, but
did not reach statistical significance (P¼0.11). The
overall magnitude of the responses mounted by
the donor CD4þ T cells suggests a haplotype dose
effect in which the lowest responses were shown by the
G1m1 homozygous donors, the highest overall responses
by the nG1m1 homozygous donors and an intermedi-
ate response by the heterozygous donors (Figure 4b).
This result suggests that the G1m1 phenotype may be
inducing tolerance to the CH315 29 sequence, but that
tolerance induction is occurring stochastically.
CD4þ T-cell proliferative responses to CH3 region peptides
are accompanied by cytokine production
Culture supernatant samples from two donors were
tested for the presence of cytokines on day 5 (Figure 5).
The donor in Figure 5a was homozygous for the nG1m1
allotype and is a robust responder to CH315 29 and to the
G1m1 sequence-containing peptides immediately up-
stream (peptides A5 and A6). Interleukin (IL)-13 and
IL-2 are detectable in all the three peptide responses.
Interferon (IFN)-g is present in the responses to CH315 29
and peptide A5, but not A6. Consistent with the low
level of proliferation, negligible cytokine responses are
seen in the N-peptide series. The donor in Figure 5b was
heterozygous for the G1m1 allotype and responded
poorly to all of the peptides, mounting only a modest
proliferative response to CH315 29. Consistent with this
reduced response, small amounts of IL-2 are found in the
CH315 29-containing wells.
All supernatants were found negative for IL-4, IL-5,
IL-10, IL-12p70, tumor necrosis factor (TNF)-a, IL-6, IL-1,
RANTES and MCP-1. The presence of IL-2, IL-13 and
IFN-g suggests that the CD4þ T cells responding to
CH3359 373 display an intermediate, or Th0, phenotype.
They are not classifiable as either Th1-like or Th2-like
even though they are expressing both Th-1-associated
(IFN-g) and Th2-associated (IL-13) cytokines.
HLA–DR associations with responses to the CH3 peptides
All 80 donors were also HLA-DRB1 and HLA-DQB1
typed. No significant correlations were found between
the HLA class II genotype of the donor and response
rate to any peptide in the set. However, the magnitude
of the proliferative response to CH315 29 was higher in
nG1m1 donors who were also HLA-DRB1*07þ (average
SI¼4.87±1.11 vs 2.11±0.23; Po0.03; Figure 6). Interest-
ingly, the effect of HLA-DRB1*07 and nG1m1 genotypes
on the response to CH315 29 were synergistic, in which
the expected response rate of the HLA-DRB1*07þ
responders and the nG1m1 responders were not simply
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Figure 3 CD4þ T-cell responses to the G1m1 and nG1m1 peptides separated by donor G1m1 status. The data from Figure 2 were segregated
according to the G1m1 allotype expression of the donor. (a, b) nG1m1 homozygous donors (n¼28). (c, d) G1m1 homozygous donors (n¼23).
(e, f) Heterozygous donors (n¼29).
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Genes and Immunityadditive. The effect is not additive because taking G1m1
homozygous/HLA-DRB1*07 negative donor responses
as a reference (mean SI¼2.11), G1m1 homozygous/
HLA-DRB1*07 positive donor responses have an SI that
is 2.8% lower (mean¼2.05). The nG1m1 homozygous/
HLA-DRB1*07 negative donor responses display an
average SI that is 18.5% higher than responses from
G1m1 homozygous/HLA-DRB1*07 negative donors
(mean SI¼2.50). If the effects were additive, we would
expect that nG1m1 homozygous/HLA-DRB1*07 re-
sponses to have a mean stimulation index 15.7%
(18.5±2.8)%) higher than the reference group. Instead,
these donors have a mean stimulation index that is
130% higher than the reference group (mean SI¼4.87;
Figure 6). This non-additive influence is statistically
significant (Po0.02). This analysis suggests that the
nG1m1, HLA-DRB1*07 homozygous donors carry
CD4þ T cells capable of recognizing and proliferating
in response to a peptide present in the CH3 region of the
g1 isotype, and that heterozygous and G1m1 homo-
zygous HLA-DRB1*07 donors contain CD4þ Tcells that
are specifically not responding to this peptide.
CD4þ T-cell responses to G1m1 allotype-containing Fc
fragments from commercial antibodies
Fc fragments were purified from commercially available
bevacizumab, infliximab and adalimumab therapeutic
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Figure 4 G1m1/nG1m1 heterozygous donors display an inter-
mediate response pattern to the CH315 29 peptide. (a). The percent
responders and the average stimulation index for the G1m1
homozygous (open circle), nG1m1 homozygous (black diamond)
and heterozygous donors (black square) are shown plus or minus
the s.e.m. of the stimulation index response. (b) The response rates
of the G1m1 homozygous, nG1m1 homozygous and heterozygous
donors are shown.
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Figure 5 CD4þ T-cell cytokine responses to the CH3 allotype-
region peptides. Supernatants from proliferative responses of
CD4þ T cells co-cultured with autologous dendritic cells and
allotype region peptides were tested for the presence of human
cytokines by a multiplex assay. Black bar: IFN-g; white bar: IL-13;
gray bar: IL-2. CD4þ T-cell proliferative response to each peptide is
shown by the black triangles. Donor in (a) was homozygous for
nG1m1. The donor in (b) was heterozygous for G1m1.
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Figure 6 HLA-DRB1*07þ and nG1m1 homozygous donor CD4
T-cell responses to CH315 29. Average stimulation index values
for donors positive for HLA-DRB1*07 at one allele (black bars)
were compared with all other donor results (open bars). Donors
who were nG1m1 homozygous and HLA-DRB1*07 positive
displayed significantly higher average stimulation indexes than all
other combinations (Po0.03). HLA-DRB1*07þ/nG1m1 homo-
zygous n¼11. HLA-DRB1*07-/nG1m1 homozygous n¼17. HLA-
DRB1*07þ/other allotype n¼14. HLA-DRB1*07-/all other
allotype n¼38.
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Genes and Immunityantibodies. Infliximab and adalimumab contain a g1
constant region that carries the G1m1 allotype, whereas
bevacizumab contains a g1 constant region that was
modified to carry the nG1m1 allotype. These two
antibodies are expressed in mammalian cells but from
different species; infliximab is produced in a murine
SP2/0 cell line, whereas bevacizumab is expressed in
CHO cells. The use of different expression cell lines
could lead to differences in the glycosylation patterns of
the two Fc fragments. Peripheral blood mononuclear cell
(PBMC) from a series of donors homozygous for nG1m1
or G1m1 were tested in vitro for proliferative responses to
the two different allotype-carrying Fc proteins (Figure 7).
A total of five G1m1 homozygous donors and four
nG1m1 homozygous in-house donors were tested. The
Fc proteins were tested as soluble proteins (Figure 7a), or
in a heat-denatured format (Figure 7b). The results were
similar for both protein formats. PBMC from donors
homozygous for nG1m1 proliferated more strongly in
the presence of the G1m1þ Fc protein than the nG1m1
Fc protein. PBMC from donors who were G1m1
homozygotes did not respond to either of the Fc proteins.
This result suggests that the G1m1 allotype sequence is
potentially immunogenic in nG1m1 donors and implies
tolerance induction in the donors who carry the G1m1
haplotype. We did not consider the presence or absence
of the G1m2 (or G1m(x)) allotype in these experiments.
Processing of the Fc fragment of human IGHG1 by
asparaginyl endopeptidase reveals a proteolytic clip site
at the G1m1 sequence
We reasoned that the unique amino-acid sequence at the
G1m1 allotype might represent a proteolytic cleavage site
that could alter the processing and presentation of the g1
constant region. Presentation of the CH315 29 fragment
could result in tolerance induction or deletion of CD4þ
T cells with this specificity. Alternatively, a unique clip
site could result in modified processing such that the
CH315 29 peptide fragment is not presented. Asparaginyl
endopeptidase (AEP; legumain) is a proteolytic enzyme
active in the antigen-processing pathway.
28 Human AEP
has been demonstrated to cleave immediately after both
asparagine and aspartic-acid residues during autocata-
lysis to its fully functional mature form.
29,30 As the G1m1
amino-acid modification contains an aspartic-acid resi-
due at position D12, we performed an in vitro proteolysis
experiment using purified recombinant human AEP. The
AEP cleavage assay was performed on both purified Fc
fragments (Figure 8a lanes 2 and 4) and intact IgG
molecules (Figure 8a lanes 1 and 3). We performed the
assay on Fc and IgG proteins that were constructed to be
identical except for the presence or absence of the G1m1
allotype in the CH3 of the constant region. After
digestion with AEP, we noted a fragment at B3.5kDa
in the G1m1-carrying Fc and IgG protein digests
(fragment d, lanes 1 (IgG) and 2 (Fc)) that was not
apparent in the nG1m1 Fc or IgG reactions (lanes 3 (IgG)
and 4 (Fc)). The protein fragments labeled b (B4kDa)
were apparently identical in both the G1m1 and nG1m1
Fc digests, and N-terminal sequencing showed that
the fragment b amino-acid sequence initiated at CH2
A78. Fragments c and d were found to have identical
N-terminal sequences that initiated at CH2 K109, but
were different in size by B500Da. Our interpretation of
this data is that the carboxy terminal ends of the protein
fragments c and d were different and that the size
difference was consistent with an AEP-mediated cleavage
event at the approximate site of the G1m1 amino-acid
modification. Fragment a is the result of an initial clip at
N326 that cleaves the Fc protein approximately in half
(12.4 and 13.6kD fragments). The putative AEP cleavage
sites in the g1 constant region were reconstructed from the
N-terminal sequencing data and from the molecular weight
of the Fc-derived fragments (Figure 8b).
Discussion
We tested a set of peptides encompassing the G1m1
allotype of human IGHG1 CH3 in human CD4þ T-cell
proliferation and cytokine secretion assays. We found
that the CH315 29 region induced proliferative and
cytokine responses in B30% of all community donors
tested. We confirmed this result in two additional tests
with newly synthesized peptides and in discrete random
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Figure 7 CD4þ T-cell proliferative responses to G1m1 allotype-
containing Fc fragments. The G1m1-containing Fc fragment purified
from infliximab after papain cleavage (closed symbols) and the
nG1m1-containing Fc fragment purified from bevacizumab after
papain cleavage (open symbols) were co-cultured with CD4þ
T cell-enriched PBMC from G1m1 homozygous (circles) or nG1m1
homozygous (squares) donors. (a) Fc fragments were titered into
cultures as soluble proteins. (b) Fc proteins were heat-denatured for
5min at 951C then cooled to room temperature. Proliferation was
assessed by tritiated thymidine incorporation on day 6. s.e.m. is
only shown on the infliximab Fc fragment proliferative responses
for clarity.
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Genes and Immunitydonor sets. Responding donors carried at least one allele
of the nG1m1 allotype in their genome. The CH315 29
peptide sequence may therefore represent a CD4þ T-cell
epitope in a specific subset of human donors. This result
suggests that IgG1-based therapeutic antibodies that
carry the G1m1 allotype in their CH3 regions may in
fact contain a CD4þ T helper epitope. The presence of a
CD4þ T-cell epitope in the Fc region of a therapeutic
antibody may both provoke and support a T-dependent
anti-idiotype response to the therapeutic.
31
We were surprised to find a CD4þ T-cell epitope not
in the allotype-containing CH312 14 region, but rather
immediately downstream of it. On further investigation,
CD4þ T-cell proliferative and cytokine responses to the
conserved peptide region were found only in cells from
donors carrying the nG1m1 allotype. Donors homozy-
gous for G1m1 did not respond to the CH315 29 peptide
above background rates. In addition, we found that the
allotype amino acids confer a unique AEP cleavage site
in G1m1þ immunoglobulin molecules. These results
show that the tolerance is induced to this conserved
peptide only in G1m1 homozygous subjects, and
nG1m1þ donors are incompletely tolerized in vivo and
therefore, mount proliferative responses to the epitope
peptide. As a similar percent of heterozygous donors as
the nG1m1 homozygous donors are mounting responses
to the CH315 29 peptide (B40% for both sets of donors),
but their overall magnitude of response is lower, our
hypothesis is that only the high affinity CD4þ T cells
specific for CH315 29 are deleted in heterozygous donors
due to a lower ‘dose’ of the processed peptide. In G1m1
homozygous donors, most CD4þ Tcells with specificity
for the CH315 29 peptide are functionally deleted because
of the increased relative dose of the peptide in vivo.A n
alternative hypothesis is that responses to the CH315 29
peptide are secondary responses in nG1m1 donors, and
G1m1 homozygous donors do not carry secondary T-cell
responses to the epitope as AEP processing destroys
epitope presentation.
32 If processing destroys the epi-
tope, the nG1m1 Fc protein should provide an intact
epitope for recognition by CD4þ T cells from G1m1
homozygous donors. Our in vitro proliferation data with
Fc-derived proteins do not support this hypothesis. The
corollary to this conclusion is that G1m1 donors’ non-
responsiveness to the Fc-derived proteins is therefore
due to tolerance induction, which supports our hypoth-
esis. That human constant regions are subjected to
processing and presentation has been described,
33 and
presentation of human G1m1 allotype-associated pep-
tides is consistent with data from mouse models where
murine allotypes can be encountered as antigenic
proteins.
3,22 Finally, this hypothesis is consistent with
the demonstration that changes of amino acids in the
sequence of constant regions can result in an immuno-
genic Fc-based protein construct.
34–36
Homozygosity of the nG1m1 allotype occurs only in
Caucasiods, and at a rate of B40% (see ref. 8) The
remaining 60% are heterozygous, or homozygous for the
G1m1 allotype. The G1m1 allotype is found at 100% of
the population in all other ethnicities. It would be logical,
therefore, to construct humanized therapeutic antibodies
using the most prevalent allotype. However, our result
suggests that administering an IgG1 therapeutic anti-
body carrying the G1m1 allotype might provoke a
CD4þ T-cell response in nG1m1 subjects, similar to
responses to allotypes observed in mice and rats.
19,25–27
AT helper response directed at the constant region could
be akin to the ‘carrier protein’ situation, where B cells
with specificity for the idiotype of the therapeutic could
receive immunological help for the Fc-specific CD4þ
T cell.
At the present time there is little published data from
human clinical studies characterizing the allotype status
of patients who develop human anti-human(ized) anti-
body (HAHA) responses.
37,38 Both of these published
studies tested for antibody development to chimeric
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Figure 8 The G1m1 allotype creates a novel AEP cleavage site. (A) Sodium dodecyl sulfate-PAGE of AEP cleavage of G1m1- and nG1m1-
containing Fc and IgG1 proteins. Lane 1: AEP-treated IgG1-G1m1 antibody. Lane 2: AEP-treated Fc-G1m1 fragment. Lane 3: AEP-treated
IgG1-nG1m1 antibody. Lane 4: AEP-treated Fc-nG1m1 fragment. Molecular weight markers are shown in kD. (a–d) fragments excised for
N-terminal sequencing. (B) Proposed AEP cleavage sites in the CH2-CH3 domains of the IGHG1 isotype. The labeled black bars indi-
cate N-terminal regions of sequenced protein fragments. The triangle indicates the approximate position of the proposed G1m1-specific
cleavage site.
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were constructed using an IGHG1 constant region gene
sequenced, and identified in 1982 that contained the
G1m1 allotype.
39,40 These included alemtuzumab, an
anti-CD52 monoclonal antibody, infliximab, an anti-TNF-
a antibody, huAb A33, a complementarity determining
regions-grafted anti-human A33 monoclonal antibody
and the fully human monoclonal antibody derived by
phage display, adalimumab.
41 All of these antibodies
induced HAHA in a significant number of patients.
Allotype analysis of HAHA-producing patients in an
early alemtuzumab rheumatoid arthritis trial suggested
that allotype differences did not correlate with the
development of HAHA as even allotype-matched pa-
tients were capable of expressing antibodies against
alemtuzumab.
38 However, the patient sample size was
quite small and this observation does not preclude the
development of anti-allotype helper cells in some
patients. The recent study of infliximab-treated patients
found no statistical correlation between G1m1 allotype
and the development of antibodies to infliximab (ATI).
However, reanalysis of the frequency of heterozygous
and nG1m1 homozygous donors as a group showed a
comparative enrichment for the nG1m1 allotype in the
ATI+ and the high titer ATI+ donors as compared to ATI
negative, and the control sample distributions.
37 No anti-
constant region-specific antibodies were detected in
huAb A33-treated patients.
42 This result does not address
whether allotype-specific helper cells supported the
development of the HAHA response. Finally, the fully
human antibody adalimumab can induce neutralizing
antibody responses in a significant number of patients.
43
HAHA responses to adalimumab have not been fully
characterized as yet, but the majority of the response is
likely to be directed at the V domain, as neutralization of
efficacy is a consequence of HAHA development.
44 It
would be of distinct interest to characterize the allotype
status of human patients generating anti-human anti-
bodies to adalimumab as the overt immunogenicity of
the infliximab, and alemtuzumab variable domains may
have overshadowed any contribution from putative
allotype-specific helper T cells.
Interestingly, during the humanization of the anti-
P185
HER2 murine monoclonal antibody, the human
IGHG1 isotype was modified from G1m1 to nG1m1,
creating the non-natural haplotype G1m17, nG1m1
(or G1m(z,  )) present in trazutzumab.
45 Although it is
difficult to compare the relative immunogenicity of
various therapeutic antibodies, the trastuzumab anti-
body molecule has not induced measurable immune
responses in many breast cancer patients.
46 It would be
of significant interest to understand whether allo-
type-specific helper T cells in certain individuals were
responsible for the development of neutralizing HAHA
reactions, as these drugs can be efficacious but are very
expensive to administer.
47 In this respect, the G1m1
status of patients could be a potential biomarker for
HAHA development.
In conclusion, we show that the G1m1 allotype of the
IGHG1 isotype of human antibodies associates with a
CD4þ proliferative and cytokine response in human
donors homozygous for the nG1m1 allotype. Proteolytic
cleavage at the allotype amino acids may reveal a novel
epitope in G1m1 donors, which in turn may result in
epitope-specific tolerance induction only in G1m1
positive donors. If our observation in vitro holds true
for exogenously administered antibodies in humans,
the G1m1 status of patients could be screened before
administration of G1m1-carrying antibodies. Finally, our
findings may be of relevance to the engineering of future
antibody therapeutics to reduce the human immune
responses elicited to these proteins.
Materials and methods
Peptides
All peptides were manufactured as consecutive 15-mers
overlapping by 12 amino acids (Table 1). Two sep-
arate sets were tested and the data were compiled. One
set was synthesized by Pepscan Systems (Lelystad,
The Netherlands), and a second set by Mimotopes
(Melbourne, Victoria, Australia). Peptides were pin-synthe-
sized, cleaved and lyophilized. On arrival the peptides
were resuspended in DMSO at B2mgml
 1. After resus-
pension, the peptide stocks were kept at  801C.
Proteins
The Fc fragment (hinge-CH2-CH3) of various human
IgG1 commercial and in-house antibodies was purified
after treatment with immobilized papain (Pierce Chemi-
cals, Rockford, IL, USA). Briefly, antibodies were
incubated at 371C with immobilized papain as per
manufacturer’s instructions for 4h to overnight. Proteo-
lysis was assessed by high-pressure liquid chromatogra-
phy. Fc fragments were purified from the protease-
treated antibodies by immobilized protein A-sepharose
(Pierce Chemicals). Purity was assessed by sodium
dodecyl sulfate-PAGE. Purified Fc was dialyzed against
phosphate-buffered saline overnight, and was filter
sterilized. Endotoxin levels were monitored by LAL
assay (Endosafe, Charles River, Wilmington, MA, USA)
and were less than 1 EU per mg protein.
CD4þ T-cell proliferation assays
PBMC samples were drawn from community donors at
the Stanford Blood Center (Palo Alto, CA, USA). The
CD4þ T-cell proliferation assay was performed as
described.
48,49 Briefly, dendritic cells were differentiated
from human peripheral blood monocytes by culture in
AIM V media (Invitrogen, Carlsbad, CA, USA) plus
GM-CSF and IL-4 for 5 days. Dendritic cells were
activated by the addition of IL-1 and TNF-a and then
collected for use on day 7. Autologous CD4þ T cells
were isolated by negative selection from thawed PBMC
samples (Stem Cell Technologies, Vancouver, British
Columbia, Canada) then co-cultured with irradiated
dendritic cells and peptides (5mgml
 1) in AIM V media
for 5 days. CD4þ T cells were used at 2 10
5 cells per
well, with 2 10
4 dendritic cells as antigen-presenting
cells. Proliferation was assessed on day 6. A donor was
considered a responder for a specific peptide if the
average proliferation of the experimental wells was 2.95
times higher than the control DMSO only wells. This cut-
off value has been validated to return the highest
sensitivity of positive versus false positive responses.
21
Validation of the cut-off value was assessed by perform-
ing CD4þ T-cell proliferation assays using peptides
derived from a number of well-characterized protein
antigens, such as staphylokinase and HPV E6 and E7 and
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mapping results. The positive control for the assay
was tetanus toxoid included in 2–4 replicate wells at
1.25mgml
 1. The tetanus toxoid positive control must
reach a stimulation index of at least 3.0 for the peptide
proliferation results to be included in the database. All
assay wells contained 0.25% DMSO, including the
tetanus toxoid positive controls and the no-peptide
negative controls.
Cytokine assays
On day 5 of incubation, 20ml samples were removed
from the cell culture wells and replicates were pooled.
Human cytokine levels were determined using the
Upstate Beadlyte 12-plex system (Millipore, Billerica,
MA, USA). Analytes tested were IL-1b, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12p70, IL-13, IFN-gamma, TNF-alpha,
RANTES and MCP-1. Data were analyzed on a Lumi-
nex-100 device (Luminex, Austin, TX, USA).
Low-resolution HLA class II typing and G1m1 allotype
determination
HLA class II typing was performed using the Dynal SSO
PCR-based system (Invitrogen). The G1m1 allotype of
donors was determined by nested PCR amplification
followed by genomic sequence analysis. First, a 503bp
fragment containing the CH3 region of IgG was
amplified from donor genomic DNA using the Expand
High Fidelity PCR System (Roche, Indianapolis, IN,
USA) with IgG class-specific forward primer 50-ATGGA
CAGAGGCCGGCTCG-30 and reverse primer 50-GTGC
TTTATTTCCATGCTGGG-30. A total of 35 cycles of
amplification (300 at 951C, 300 at 651C, 450 at 721C) were
performed in the buffer provided by the manufacturer.
Next, a 414bp fragment containing the G1m1 allotypic
sequence of IgG1 was amplified from the first PCR
product using the Expand High Fidelity PCR System
with IgG1 subclass-specific forward primer 50-AGAGT
GACCGCTGTA-30 and reverse primer 50-AAGCATCC
TCGTGCGACCG-30. Furthermore, 35 cycles of amplifi-
cation (300 at 951C, 900 at 721C ) were performed in
Buffer D (Invitrogen). Finally, PCR products were
sequenced on an ABI 3700 sequencer (Applied Biosys-
tems, Foster City, CA, USA). Homozygosity and hetero-
zygosity were apparent by an analysis of the sequencing
traces.
PBMC Fc protein proliferation assays
Peripheral blood samples were obtained from G1m1-
typed in-house donors. PBMCs were isolated by density
centrifugation, and monocytes and CD4þ T cells were
enriched by positive selection with anti-CD4þ magnetic
particles (Stem Cell Technologies). CD4þ enriched
PBMCs were cultured at 2 10
5 cells per well in AIM
V media. Sterile, endotoxin-free Fc fragment proteins
were titered into the wells, and the cultures were
incubated for 5 days. Proliferation and IFN-g secretion
were assessed on day 6. Fc fragment proteins were tested
either as soluble protein, or after heat denaturation at
1001C for 5min.
Asparaginyl endopeptidase activity assay
Purified IgG1 antibodies from constructs containing
either the G1m1 or nG1m1 mutation were treated
with immobilized papain (Thermo Scientific, Rockford,
IL, USA) and the Fc fragments were purified using
immobilized protein A (Thermo Scientific). Fc digestion
was performed in 50mM sodium acetate, 100mM sodium
chloride, pH 4.0, with 5mM DTT and 175 units of
recombinant human legumain (AEP, R and D Systems,
Minneapolis, MN, USA) per 1ug of protein. The reaction
was allowed to progress overnight at 371C. The digested
protein was separated on sodium dodecyl sulfate-PAGE
gels, and the appropriate bands were excised for
N-terminal sequencing (Commonwealth Biotechnolo-
gies, Richmond, VA, USA).
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